Kevin Silver, MD
Interventional Cardiology · Akron, OHNPI 1114923380
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,609 of the $13,748 with a category attached, or 62.6%. 17 manufacturers reported payments, led by Abbott at 38.1% of the total. Reporting peaked in 2023 at $6,317 and has fallen 77.3% since, to $1,436 in 2025.
Across 151 payments — averaging $91.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Janssen Research & Development, LLC$2K
- Abiomed$1K
- Medtronic$1K
- Boston Scientific$1K
- Novartis$855
- plus $2K from 11 others
Across 188 payments — averaging $2650.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$265K
- CSL Behring$125K
- Esperion Therapeutics, Inc.$56K
- Janssen Research & Development, LLC$53K
What the payments were for
- Grants$550%
- Travel & lodging$4,69734%
- Food & beverage$8,60963%
- Education$3873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 52 | $5,235 |
| Janssen Research & Development, LLC | 10 | $2,038 |
| Abiomed | 28 | $1,434 |
| Medtronic(2 entities) | 16 | $1,143 |
| Boston Scientific | 9 | $1,085 |
| Novartis | 4 | $855 |
| Shockwave Medical, Inc | 6 | $638 |
| Inari Medical, Inc. | 4 | $582 |
| Stryker | 7 | $268 |
| Cardiovascular Systems Inc. | 5 | $158 |
| Philips North America LLC | 2 | $107 |
| Terumo Medical Corporation | 2 | $90 |
| Cordis US CORP. | 2 | $49 |
| Angiodynamics, Inc. | 1 | $23 |
| Livanova USA, Inc. | 1 | $18 |
| EKOS Corporation | 1 | $14 |
| Medline Industries LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,337
- OPTIS$1,174
- LEQVIO$855
- Impella$808
- FLOWTRIEVER CATHETER, S$697
- Diamondback Coronary$609
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$469
- CT THROMBECTOMY SYSTEM KIT$325
- Xience Sierra Coronary Stent System$319
- ONYX FRONTIER$318
- AVVIGO Guidance System$297
- XIENCE SIERRA$265
- GENERAL - THERAPIES$187
- CROSSBOSS$140
- Vascular Lithotripsy$119
- Euphora$115
- Resolute$108
- ONYX 18$100
How this compares
$13,748 in reported general payments places this provider in the 70th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $107,590 |
| EntrestoSacubitril/Valsartan | 21 | $29,210 |
| FarxigaDapagliflozin Propanediol | 19 | $27,504 |
| JardianceEmpagliflozin | 14 | $22,274 |
| BrilintaTicagrelor | 12 | $13,872 |
| Enoxaparin Sodium | 34 | $4,113 |
| Rosuvastatin Calcium | 96 | $4,060 |
| Warfarin Sodium | 377 | $3,898 |
| Ezetimibe | 56 | $2,409 |
| Metoprolol Succinate | 159 | $2,151 |
| Atorvastatin Calcium | 182 | $2,030 |
| Nitroglycerin | 138 | $1,283 |
| ClopidogrelClopidogrel Bisulfate | 105 | $935 |
| Pantoprazole Sodium | 89 | $833 |
| JantovenWarfarin Sodium | 73 | $775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $855 | $29,21021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Akron
- Justin DunnAkron$133K
- Negar SalehiAkron$40K
- Peter BittenbenderAkron$30K
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.